Clinical Trials Logo

Filter by:
NCT ID: NCT05990166 Recruiting - Iron Deficiency Clinical Trials

Assessing the Effect of a Mineral-enriched Powder on Iron Deficiency in Women of Reproductive Age

Start date: April 27, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to determine if taking a mineral-enriched powder can raise blood iron levels compared to a placebo powder in reproductive-aged women with iron deficiency. The main questions it aims to answer are: - Does the mineral-enriched powder raise blood iron levels compared to a placebo powder in women when it is taken every day for six months? - How many participants still have iron deficiency after six months of taking the mineral-enriched powder compared to a placebo powder? Participants in this clinical trial will drink the mineral-enriched powder containing ferrous iron and zinc sulphate monohydrate or a placebo powder mixed with 1 litre of water daily for six months. The placebo is a look-alike substance that does not contain active ingredients (iron and zinc). Participants will also have to: - Complete an online "study diary" every two weeks for six months - Provide a blood sample once a month for six months - Attend three in-person visits with a researcher, at enrolment (baseline), midline (three months), and endline (six months) - Complete three sets of online questionnaires (following each in-person visit) - Complete three sets of dietary assessments (following each in-person visit) - Provide three stool samples (following each in-person visit)

NCT ID: NCT05989659 Recruiting - Clinical trials for Chronic Kidney Diseases

Transitioning to Home or In-center Dialysis

TRANSIT-CARE
Start date: January 1, 2023
Phase:
Study type: Observational

For people with advanced kidney disease, deciding which type of dialysis is best can be challenging. Studies have shown that quality of life is very important to patients. It is thought that the quality of life of people receiving their dialysis at home may be better than the one of people receiving dialysis in a hospital. However, how the start of dialysis changes the quality of life of people who choose home dialysis in comparison to people choosing dialysis in a hospital is still unknown. TRANSIT-CARE is a prospective mixed methods study following adult with advanced kidney disease who progress to dialysis and receive home or hospital-based dialysis. This study aims to examine the trajectory and change in patients' quality of life and their frailty status (health, mobility and function) before start of dialysis and up to 12-month after start. Differences between people doing home dialysis and hospital-based dialysis will be assesses taking into account people's characteristics including their gender and socio-demographics characteristics. The study will include questionnaires to measure quality of life and tools to evaluate frailty. Additionally, semi-structured interviews will be done with a diverse group of patients and caregivers before and after the initiation of dialysis to better understand their experience of transitioning to dialysis.

NCT ID: NCT05989477 Recruiting - Patient Engagement Clinical Trials

At-home Breast Oncology Care Delivered With E-health Solutions

ABODE
Start date: June 22, 2023
Phase: N/A
Study type: Interventional

The COVID-19 pandemic has significantly impacted healthcare service delivery, highlighting the need for high quality virtual patient care. Our team has developed a multi-dimensional remote eHealth solution for newly diagnosed breast cancer patients and their practitioners to use during the diagnostic and follow-up period. The ABODE study involved development of a Breast Cancer Treatment Application (app) which will facilitate virtual consultations, deliver patient education material, and collect patient reported outcome measures (PROMs). Using a randomized controlled trial design, the team will evaluate a variety of outcomes for breast cancer patients who will use the app throughout their diagnosis and treatment period. Primary Objective: To compare changes in patient activation (assessed by PAM-13) over 1 year among newly diagnosed breast cancer patients between those using the app and those receiving standard care. Secondary Objectives: 1. Compare additional PROMs between the standard care and intervention groups 2. Describe health service outcomes among app users 3. Explore end-user experience of using the app 4. Measure activity levels using wearable devices

NCT ID: NCT05989178 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Prospective Recurrent Pregnancy Loss Registry

Start date: July 12, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this Registry is to prospectively collect data of Recurrent Pregnancy Loss (RPL) patients attending the specialized care centre at the BC Women's Hospital, in order to evaluate investigation practices, treatment options, and outcomes for this patient population over time.

NCT ID: NCT05987449 Recruiting - Hemophilia A Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Start date: September 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Study WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter, multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. The aim is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of multiple ascending doses of NXT007.

NCT ID: NCT05987332 Recruiting - Clinical trials for Metastatic Uveal Melanoma

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Start date: October 31, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

NCT ID: NCT05986929 Recruiting - Clinical trials for Communication, Multidisciplinary

Acceptability, Barriers and Facilitators of a Communication Tool in Hospital Settings

Start date: January 1, 2024
Phase:
Study type: Observational

The presence of appropriate systems to promote good communication within the care team is one of the ten important characteristics identified for effective interdisciplinary work. However, the current communication systems at the Eastern Townships University Health and Social Services Centre of the Sherbrooke University Hospital (SUH), an hospital setting in Sherbrooke (Quebec, Canada), are numerous, scattered and difficult to identify quickly. The bedside magnetized posters were developed to address this issue. The use of this kind of tool should improve teamwork, communication, and patient care. As the bedside magnetized posters are now well established on the stroke and geriatric units at the SUH, it is essential to evaluate their acceptability by staff members. In addition, identifying the barriers and facilitators to their use will support the team for eventual deployment in other care environments at the SUH.

NCT ID: NCT05986513 Not yet recruiting - Chronic Pain Clinical Trials

Brain MRI for Knee OA

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

It has been estimated that 300 million people worldwide have osteoarthritis (OA), and this has increased by 97% over the past 25 years. OA is degenerative joint disease that has joint cartilage break down and causes the surrounding bone to change and rub. The pain and loss of mobility experienced by people with knee OA can seriously reduce quality of life, while pain management causes significant healthcare spending. Unfortunately, the pain associated with OA is complex and difficult to treat other than to have a total knee replacement surgery to replace the damaged bone and surrounding tissues with artificial ones. Our research study plans to use advanced magnetic resonance imaging techniques and novel analysis methods to determine if specific parts of the brain are responsible for difficult to describe and diagnose aspects of chronic pain. This study will help us better understand the effects of chronic pain in the brain and the results will help guide future research into new therapeutic options that would focus on relieving the brain dysfunction caused by chronic pain.

NCT ID: NCT05986370 Recruiting - Clinical trials for Chronic Low-back Pain

The METRIC Study Protocol

METRIC
Start date: October 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the effects of spinal manipulative therapy in individuals with chronic primary low back pain and determine the neurophysiological mechanisms underlying pain relief. The main questions it aims to answer are: • Is pain relief produced by spinal manipulative therapy in patients with chronic primary low back pain caused by a reduction of C-fiber-related nociceptive processing? • Are these effects greater when spinal manipulative therapy is applied to the whole spine where it is clinically indicated compared with lumbar spine only? • Are these effects greater after 36 treatments over 3 months compared with 12 treatments over 1 month. Participants will receive spinal manipulative therapy (all clinically indicated spine segments or back only) or a control intervention. A group of healthy volunteers will be recruited to assess secondary outcome measures over the same time period, as reference data for comparisons. Researchers will compare the two groups receiving spinal manipulative therapy to the group receiving the control intervention to see if clinical pain relief and the reduction of temporal summation of second pain (produced experimentally) is significantly greater with spinal manipulative therapy.

NCT ID: NCT05986318 Not yet recruiting - Lung Cancer Clinical Trials

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

RESPIRE-ILD
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.